FIELD: medicine.
SUBSTANCE: method involves determining glypicane-3(GPC3) quantity in blood serum, blood plasma or whole blood sample taken from organism patient having hepatopathy or belonging to hepatocellular carcinoma risk group and interpreting GPC3 availability data for diagnosing hepatocellular carcinoma cases. Antibodies are produced that show properties of specific binding to GPC3.
EFFECT: rapid noninvasive diagnosis method of improved specificity.
23 cl, 5 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL TUMOUR BIOMARKER | 2010 |
|
RU2567005C2 |
| MUTANT STRAIN OF HEPATITIS B VIRUS AND ITS USING | 1998 |
|
RU2270863C2 |
| TUMOUR-REJECTING GLYPICAN-3 (GPC3)-DERIVATIVE ANTIGENIC PEPTIDES USED FOR HLA-A2-POSITIVE PATIENTS, AND PHARMACEUTICAL PRODUCT CONTAINING SAID PEPTIDES | 2006 |
|
RU2395519C2 |
| ANTIBODIES AGAINST HEPATITIS B VIRUS AND THEIR USE | 2020 |
|
RU2803082C2 |
| CANCER DETECTION BY HIGH BCL-2 LEVELS | 2007 |
|
RU2436098C2 |
| NEW TUMOUR BIOMARKER | 2010 |
|
RU2714750C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS | 2012 |
|
RU2641968C2 |
| ANNEXIN A3 MONOCLONAL ANTIBODIES FOR DETECTION OF PROSTATE CARCINOMA | 2007 |
|
RU2467335C2 |
| IMPROVED REP PROTEIN FOR USE IN DIAGNOSTIC ANALYZES | 2018 |
|
RU2736275C1 |
